In May 2021, the Food and Drug Administration (FDA), where we work, approved sotorasib (Lumakras) for metastatic non–small-cell lung cancers (NSCLCs) harboring the KRAS p.G12C mutation. Sotorasib, which was approved on the basis of the phase 2 portion of the CodeBreaK100 trial, is the first drug to…
Read the full post on The New England Journal of Medicine: Search Results in Health Policy
